Harmonigenic Corporation (HC) is an innovative diagnostic company with the vision of offering healthcare providers greater accuracy of metastasis prediction in cancer diagnosis using its patent-pending photonics assay technology. The goal is to assist doctors and patients with treatment decisions, ultimately reducing over-treatment, improving patients’ quality of life, and decreasing healthcare costs. Further development will be supported by $1.1M in secured grant funding.
Robert L. Hill, MD founded HC in 2015 after placing 2nd in the Harvardx business plan contest “Innovating in Health Care”. He negotiated an option to license & technology development agreement with U of Rochester, partnering with Dr. Edward Brown III’s lab (who has secured funding from NIH & DOD CDMRP) to validate the technology. Dr. Hill has expanded the team to include experts in operations, quality & reimbursement & will add a Lab Director.
The leading problem HC aims to address is over-treatment of cancer. Sixty percent of patients diagnosed with breast cancer have no evidence of metastasis & only 15%-25% of these are at risk of recurrence in 10 years. Meaning 75% may not benefit from systemic treatment, instead suffering the cost & side effects. Patients need more confidence in their diagnosis, doctors need more accurate prediction and payers seek better outcomes at lower cost.
Products and Services
HC’s optical diagnostic assay is a predictor of cancer metastasis called an Optical Prediction of Time Interval to Metastasis (OPTIM). This assay evaluates the extracellular matrix in the primary tumor to predict the probability of metastasis or recurrence. OPTIM will provide patients and doctors with the information needed to make treatment decisions and the healthcare industry will benefit through improved outcomes and cost reduction.
Cancer patients and oncologists need more accurate diagnostic tests that predict cancer metastasis or recurrence, to choose optimal treatment. In the USA, an estimated 144K/yr women diagnosed with breast cancer need a metastasis diagnostic. OPTIM will also aim to serve the 58K/yr stage I and 47K/yr stage II people diagnosed with colon cancer.
Our OPTIM technology will allow our central laboratory to assay diagnostic pathology tissue slides, sent by referring pathologists, in one day. To Improve our prediction & add value, we will collect electronic medical record, treatment & outcome data in a prospective registry stratified by our metastatic prediction, testing new analytic models. We will focus on metastasis prevention & root causes of metastasis to reveal new targets for treatment.
We serve patients, doctors, & payers, who want improved outcomes at lower cost. HC envisions a prognostic service providing improved accuracy of metastatic prediction over the pathology & genomic methods, with patients avoiding costly, harmful & unnecessary treatments. Insurance companies gain better patient outcomes with personalized treatment & reduced costs. Physicians engage patients in a shared decision model improving patient satisfaction.
Sales and Marketing Strategy
The primary focus of HC is to publish evidence of efficacy in scientific journals & present at major conferences. This will create awareness through advocacy groups & champion adopters. Selecting published clinical trials of the current standard of care for fast & inexpensive follow-on prospective-retrospective studies using archived tissue provides head to head comparable evidence, & rapid adoption if we demonstrate improved clinical utility.
Our patent-pending optical technology uniquely focuses on the collagen extracellular matrix (soil), instead of just the cells (seeds). Patent claims cover all solid tumors. OPTIM is nondestructive and repeatable. HC is a first-mover with such a rapid photonics assay. vimeo.com/236205023
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.